Arrowhead Pharmaceuticals Corp (ARWR)

14.51 +0.18 (1.26%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (12/11/18 *Est.)

Latest Headlines

Arrowhead Research (ARWR) PT Raised to $18 at B.Riley/FBR August 8, 2018 10:07 AM - StreetInsider Arrowhead Research (ARWR) PT Raised to $18 at Cantor Fitzgerald August 8, 2018 6:58 AM - StreetInsider Arrowhead Research (ARWR) PT Raised to $17.50 at Chardan Capital Markets August 8, 2018 6:55 AM - StreetInsider Form 10-Q ARROWHEAD PHARMACEUTICAL For: Jun 30 August 7, 2018 4:57 PM - SEC Filing Form 8-K ARROWHEAD PHARMACEUTICAL For: Aug 07 August 7, 2018 4:54 PM - SEC Filing Arrowhead Pharmaceuticals Corp (ARWR) Reports In-Line Q3 EPS, Revenues Beat August 7, 2018 4:00 PM - StreetInsider Arrowhead Pharmaceuticals Reports Fiscal 2018 Third Quarter Results August 7, 2018 4:00 PM - BizWire Arrowhead Pharmaceuticals (ARWR) Reports $10 Million Milestone Payment from Amgen August 1, 2018 7:40 AM - StreetInsider Arrowhead Pharmaceuticals Earns $10 Million Milestone Payment from Amgen August 1, 2018 7:30 AM - BizWire Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Third Quarter Results July 24, 2018 7:30 AM - BizWire Arrowhead Research (ARWR) PT Raised to $16 at Chardan Capital Markets July 2, 2018 8:29 AM - StreetInsider Arrowhead Pharmaceuticals Corp (ARWR) Highlights New Clinical Data on ARO-AAT at Alpha-1 National Education Conference June 29, 2018 7:31 AM - StreetInsider Arrowhead Presents New Clinical Data on ARO-AAT at Alpha-1 National Education Conference June 29, 2018 7:30 AM - BizWire Arrowhead Pharmaceuticals Corp (ARWR) Granted Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency June 27, 2018 7:33 AM - StreetInsider Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency June 27, 2018 7:30 AM - BizWire Arrowhead Research (ARWR) PT Raised to $17 at Jefferies June 26, 2018 7:02 AM - StreetInsider Form 4 ARROWHEAD PHARMACEUTICAL For: Jun 19 Filed by: Myszkowski Kenneth Allen June 20, 2018 9:19 PM - SEC Filing Arrowhead Pharmaceuticals Corp (ARWR) Announces Complete Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease June 18, 2018 7:30 AM - StreetInsider Arrowhead Completes Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease June 18, 2018 7:30 AM - BizWire Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) June 8, 2018 4:30 PM - BizWire Form 4 ARROWHEAD PHARMACEUTICAL For: May 30 Filed by: Myszkowski Kenneth Allen June 1, 2018 5:35 PM - SEC Filing Arrowhead Pharmaceuticals Corp (ARWR) Reports Complete Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV May 30, 2018 7:39 AM - StreetInsider Arrowhead Completes Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV May 30, 2018 7:30 AM - BizWire Arrowhead Pharmaceuticals to Present at Upcoming June 2018 Conferences May 30, 2018 7:25 AM - BizWire Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis May 21, 2018 7:30 AM - BizWire Full Article List